SEARCH

SEARCH BY CITATION

Table A1. Unit costs for hospital resource use (Euro 2009).

Table A2. Unit costs of therapy regimens for treatment of multiple myeloma (Euro 2009).

Table A3. Patient characteristics and prognostic factors at start of relapsed/refractory treatment.

Table A4. Additional descriptive statistics for mean monthly costs during relapsed/refractory treatment.

Table A5. Generalized linear model results describing the association between prognostic factors and total monthly costs.

Table A6. Additional descriptive statistics for mean monthly costs during second line per novel agent regimen.

Table A7. Additional descriptive statistics for mean monthly costs during third line per novel agent regimen.

Table A8. Additional descriptive statistics for mean monthly costs during fourth line per novel agent regimen.

FilenameFormatSizeDescription
jcpt12020_sm_TableA1.pptx53KSupporting info item
jcpt12020_sm_TableA2.pptx53KSupporting info item
jcpt12020_sm_TableA3.pptx65KSupporting info item
jcpt12020_sm_TableA4.pptx68KSupporting info item
jcpt12020_sm_TableA5.pptx52KSupporting info item
jcpt12020_sm_TableA6.pptx67KSupporting info item
jcpt12020_sm_TableA7.pptx68KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.